Dulaglutide and renal protection in type 2 diabetes Comment

被引：11
作者：
Cherney, David Z. I. [1 ,2 ]
Verma, Subodh [3 ]
Parker, John D. [4 ]
机构：
[1] Univ Toronto, Dept Med, Div Nephrol, Toronto Gen Hosp, Toronto, ON M5G 2C4, Canada
[2] Univ Toronto, Dept Physiol, Toronto, ON M5G 2C4, Canada
[3] Univ Toronto, Dept Surg, Div Cardiovasc Surg, St Michaels Hosp, Toronto, ON, Canada
[4] Univ Toronto, Dept Med, Div Cardiol, Mt Sinai Hosp,Lunenfeld Tanenbaum Res Inst, Toronto, ON, Canada
来源：
LANCET DIABETES & ENDOCRINOLOGY | 2018年 / 6卷 / 08期
基金：
加拿大健康研究院;
关键词：
POTENTIAL MECHANISMS; INHIBITION; LIRAGLUTIDE; OUTCOMES;
D O I：
10.1016/S2213-8587(18)30125-6
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：588 / 590
页数：3
相关论文
共 11 条
[1]   Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus [J].
Cherney, David Z. I. ;
Perkins, Bruce A. ;
Soleymanlou, Nima ;
Maione, Maria ;
Lai, Vesta ;
Lee, Alana ;
Fagan, Nora M. ;
Woerle, Hans J. ;
Johansen, Odd Erik ;
Broedl, Uli C. ;
von Eynatten, Maximilian .
CIRCULATION, 2014, 129 (05) :587-597
[2]   The physiological role of glucagon-like peptide-1 in the regulation of renal function [J].
Farah, Livia X. S. ;
Valentini, Vanessa ;
Pessoa, Thaissa D. ;
Malnic, Gerhard ;
McDonough, Alicia A. ;
Girardi, Adriana C. C. .
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2016, 310 (02) :F123-F127
[3]   Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications [J].
Heerspink, Hiddo J. L. ;
Perkins, Bruce A. ;
Fitchett, David H. ;
Husain, Mansoor ;
Cherney, David Z. I. .
CIRCULATION, 2016, 134 (10) :752-772
[4]   Dipeptidyl Peptidase 4 Inhibition Stimulates Distal Tubular Natriuresis and Increases in Circulating SDF-1α1-67 in Patients With Type 2 Diabetes [J].
Lovshin, Julie A. ;
Rajasekeran, Harindra ;
Lytvyn, Yulyia ;
Lovblom, Leif E. ;
Khan, Shajiha ;
Alemu, Robel ;
Locke, Amy ;
Lai, Vesta ;
He, Huaibing ;
Hittle, Lucinda ;
Wang, Weixun ;
Drucker, Daniel J. ;
Cherney, David Z. I. .
DIABETES CARE, 2017, 40 (08) :1073-1081
[5]   Sodium Glucose Cotransporter-2 Inhibition in Heart Failure Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials [J].
Lytvyn, Yuliya ;
Bjornstad, Petter ;
Udell, Jacob A. ;
Lovshin, Julie A. ;
Cherney, David Z. I. .
CIRCULATION, 2017, 136 (17) :1643-1658
[6]   Liraglutide and Renal Outcomes in Type 2 Diabetes [J].
Mann, Johannes F. E. ;
Orsted, David D. ;
Brown-Frandsen, Kirstine ;
Marso, Steven P. ;
Poulter, Neil R. ;
Rasmussen, Soren ;
Tornoe, Karen ;
Zinman, Bernard ;
Buse, John B. .
NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (09) :839-848
[7]   Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes [J].
Marso, Steven P. ;
Daniels, Gilbert H. ;
Brown-Frandsen, Kirstine ;
Kristensen, Peter ;
Mann, Johannes F. E. ;
Nauck, Michael A. ;
Nissen, Steven E. ;
Pocock, Stuart ;
Poulter, Neil R. ;
Ravn, Lasse S. ;
Steinberg, William M. ;
Stockner, Mette ;
Zinman, Bernard ;
Bergenstal, Richard M. ;
Buse, John B. .
NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (04) :311-322
[8]   Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes [J].
Neal, Bruce ;
Perkovic, Vlado ;
Mahaffey, Kenneth W. ;
de Zeeuw, Dick ;
Fulcher, Greg ;
Erondu, Ngozi ;
Shaw, Wayne ;
Law, Gordon ;
Desai, Mehul ;
Matthews, David R. .
NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (07) :644-657
[9]  
Ridker P M., J Am CollCardiol
[10]   Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial [J].
Tuttle, Katherine R. ;
Lakshmanan, Mark C. ;
Rayner, Brian ;
Busch, Robert S. ;
Zimmermann, Alan G. ;
Woodward, D. Bradley ;
Botros, Fady T. .
LANCET DIABETES & ENDOCRINOLOGY, 2018, 6 (08) :605-617
12